EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

A Pilot, Randomized Controlled Trial of Dual Daily HIV and Sexually Transmitted Infection Pre-exposure Prophylaxis Using Tenofovir Disoproxil Fumarate/Emtricitabine and Doxycycline in Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women: The DuDHS Study

Troy Grennan iD, Saira Mohammed, Joshua Edward, Tessa Tattersall iD, Amit K Gupta, Joyce Seto, Michelle Dennehy, Marc G Romney, Wendy Zhang, Jenny Li, Jason Trigg iD, Viviane D Lima iD und 5 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf043 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Troy Grennan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Prevention Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, Doxycycline, HIV Infections, Sexually Transmitted Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Men who have sex with men (MSM) and transgender women experience high sexually transmitted infection (STI) rates. This study evaluated the feasibility of doxycycline pre-exposure prophylaxis (doxyPrEP) for STI prevention in these key populations.

Methods

Sexually-active MSM and transgender women without human immunodeficiency virus (HIV) with prior syphilis were recruited. Participants initiated HIV PrEP with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) daily for 48 weeks and were randomized 1:1 to daily doxyPrEP for 48 weeks (immediate arm), or doxyPrEP initiated at 24 weeks (deferred arm). Primary outcomes included adherence, measured using questionnaires, along with tolerability; STI incidence (chlamydia, gonorrhea, syphilis) was a secondary outcome. Nasal carriage of Staphylococccus aureus was assessed serially for doxycycline resistance.

Results

Fifty-two participants were enrolled into the immediate (n = 26) and deferred (n = 26) arms. At 48 weeks, self-reported adherence (≥95%) was 75.0% versus 66.7% (P = .538) for TDF/FTC, and 70.8% versus 61.9% (P = .526) for doxycycline in the immediate versus deferred arms, respectively. No doxyPrEP-related serious adverse events occurred. Incidence of any STI at 24 weeks was reduced in the immediate versus deferred arms, and over 48 weeks, being on doxycycline (vs being off; ie, first 24 weeks of deferred arm) was associated with STI reduction (adjusted odds ratio [aOR] 0.36; 95% confidence interval [CI]: .15–.89). Emergent doxycycline-resistant S. aureus was identified in six individuals, with five in the immediate arm (P = .077).

Conclusions

Dual HIV/doxyPrEP is feasible and associated with a significant reduction in incident STI. Further evaluation of dosing strategies, efficacy and impact on antimicrobial resistance is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-Exposure ProphylaxisDoxycyclineHIV InfectionsSexually Transmitted DiseasesEmtricitabineAnti-HIV AgentsHumansMaleAdultFemalePilot ProjectsHomosexuality, MaleMiddle AgedTransgender PersonsTenofovirAnti-Bacterial Agents

Stichwörter der Autor:innen

STI preventiondoxycyclinedoxycycline pre-exposure prophylaxis (doxyPrEP)men who have sex with men (MSM)sexually transmitted infections (STI)

Substanzen

DoxycyclineEmtricitabineAnti-HIV AgentsTenofovirAnti-Bacterial Agents

Autor:innen und Institutionen

  • Clinical Prevention Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada.
  • Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
  • Pharmacokinetics Laboratory, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Department of Pathology and Laboratory Medicine, St. Paul's Hospital, Providence Health Care, Vancouver, British Columbia, Canada.

ORCID-Profile: Troy Grennan, Tessa Tattersall, Jason Trigg, Viviane D Lima, Stephen Juwono, Jason Wong

Zitieren

APA

Grennan, T., Mohammed, S., Edward, J., Tattersall, T., Gupta, A. K., Seto, J., Dennehy, M., Romney, M. G., Zhang, W., Li, J., Trigg, J., Lima, V. D., Juwono, S., Wong, J., Zhang, G., Montaner, J. S. G., & Hull, M. W. (2025). A Pilot, Randomized Controlled Trial of Dual Daily HIV and Sexually Transmitted Infection Pre-exposure Prophylaxis Using Tenofovir Disoproxil Fumarate/Emtricitabine and Doxycycline in Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women: The DuDHS Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf043

Vancouver

Grennan T, Mohammed S, Edward J, Tattersall T, Gupta AK, Seto J, et al. A Pilot, Randomized Controlled Trial of Dual Daily HIV and Sexually Transmitted Infection Pre-exposure Prophylaxis Using Tenofovir Disoproxil Fumarate/Emtricitabine and Doxycycline in Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women: The DuDHS Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf043

BibTeX
@article{Grennan2025,
  author = {Grennan, Troy and Mohammed, Saira and Edward, Joshua and Tattersall, Tessa and Gupta, Amit K and Seto, Joyce and Dennehy, Michelle and Romney, Marc G and Zhang, Wendy and Li, Jenny and Trigg, Jason and Lima, Viviane D and Juwono, Stephen and Wong, Jason and Zhang, Guijun and Montaner, Julio S G and Hull, Mark W},
  title = {A Pilot, Randomized Controlled Trial of Dual Daily HIV and Sexually Transmitted Infection Pre-exposure Prophylaxis Using Tenofovir Disoproxil Fumarate/Emtricitabine and Doxycycline in Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women: The DuDHS Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf043}
}
Kostenlos starten →